Potassium Citrate
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Potassium Citrate
- Potassium Citrate: From Potassium Deficiency and Renal Tubular Acidosis to Nephrolithiasis
Potassium Citrate: From Potassium Deficiency and Renal Tubular Acidosis to Nephrolithiasis
One-Sentence Summary
Potassium citrate is a potassium and alkali supplement, originally used for potassium deficiency, renal tubular acidosis and acute urate nephropathy. The TxGNN model predicts it may be effective for Nephrolithiasis (kidney stones), the top-ranked prediction with meaningful supporting data, with 15 clinical trials and 16 publications currently supporting this direction. Note that nephrolithiasis is largely an on-label or closely related use, so this is not a true repurposing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Potassium deficiency disease; renal tubular acidosis; acute urate nephropathy |
| Predicted New Indication | Nephrolithiasis (see note below) |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Proceed with Guardrails |
Note on prediction selection: The highest-scoring prediction (rank 1, familial visceral myopathy, 99.95%) has no trials, no literature and no plausible mechanism, so it is only a computational signal. This report focuses on nephrolithiasis (rank 4), the highest-ranked prediction with substantial clinical evidence. The other predictions (for example Pendred syndrome, cystinosis and exocrine pancreatic insufficiency) have no or only indirect evidence and are on Hold or Research Question status.
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available from the data compiled for this report. Based on known pharmacology, potassium citrate is an alkalinizing potassium salt. It raises urinary pH and urinary citrate.
Citrate binds calcium in urine and inhibits the nucleation and growth of calcium oxalate and calcium phosphate crystals. Alkalinization also helps dissolve uric acid stones. This is closely related to the drug's original renal indications (renal tubular acidosis and urate nephropathy), where low urinary citrate and acidic urine are also central problems.
There are caveats. Over-alkalinization may promote calcium phosphate stones, so urinary pH should be monitored. In addition, the potassium load poses a hyperkalaemia risk in patients with impaired kidney function.
Clinical Trial Evidence
The table lists the 10 most relevant of the 15 trials identified.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00004284 | Phase 3 | Completed | 300 | Randomized, double-blind comparison of potassium phosphate vs potassium citrate for absorptive hypercalciuria; no results are summarized in the data |
| NCT02373384 | Phase 4 | Completed | 182 | Predictors of success of oral dissolution (alkalinization) therapy in radiolucent renal stones |
| NCT06819553 | Phase 2/3 | Unknown | 48 | Randomized trial of oral potassium citrate to reduce ureteral stent encrustation after ureteroscopy for uric acid stones |
| NCT06966635 | Phase 4 | Recruiting | 312 | Potassium citrate sustained-release tablets vs sodium bicarbonate vs control in gout; effect on uric acid, flares and stones |
| NCT01754779 | Phase 2 | Completed | 13 | Citric acid or potassium citrate to reduce calcium phosphate saturation in urine; very small |
| NCT03836144 | N/A | Completed | 63 | Effect of urine alkalinization on urinary inflammatory markers in cystinuria; biomarker study |
| NCT03984409 | N/A | Completed | 22 | Dietary potassium citrate source (orange juice) for hypocitraturia and aciduria in stone formers |
| NCT03281928 | N/A | Terminated | 30 | Dietary sodium and potassium citrate effects on renal mineral handling; ended early |
| NCT05389995 | N/A | Active, not recruiting | 10 | Lemonade beverage vs potassium citrate on urinary stone risk factors |
| NCT01980004 | Phase 2 | Withdrawn | 0 | Potassium citrate for calcium phosphate stone recurrence; withdrawn, so no evidence |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27915395 | 2017 | Systematic review / meta-analysis | Urolithiasis | Summarizes randomized trials on citrate supplementation to prevent stone recurrence after shock wave lithotripsy |
| 40978115 | 2025 | Review | Clin Kidney J | Citrate acts as a urinary base equivalent and a potent inhibitor of calcium stone formation; hypocitraturia is a continuum |
| 40583613 | 2025 | Review | Arch Ital Urol Androl | Expert update on urinary stone management |
| 30531474 | 2019 | Review | Curr Opin Nephrol Hypertens | Citrate therapy for calcium phosphate stones; strategies enhancing citrate excretion have not consistently reduced recurrence |
| 30478476 | 2019 | Review | Urolithiasis | Empiric therapy for kidney stones |
| 26977089 | 2016 | Review | BMJ | Medical management of renal stones, including diet and drug prevention |
| 23924538 | 2013 | Review | Medicina | Citrate is a powerful inhibitor of calcium salt crystallization; acid pH is the main determinant of citrate excretion |
| 11475849 | 2001 | Review | Przegl Lek | Therapeutic uses of potassium citrate, including stone disease and distal renal tubular acidosis |
| 18518781 | 2008 | Review | Expert Opin Pharmacother | Pharmacotherapy of kidney stones |
| 1988724 | 1991 | Clinical study | J Urol | Bioavailability and citraturic response of potassium-magnesium citrate vs potassium citrate in 14 volunteers |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08734P | UROCIT-K TABLET 1080 mg | Tablet | Not listed in the data |
| SIN05148P | POTCIT MIXTURE | Solution | Not listed in the data |
| SIN06732P | POTASSIUM CITRATE MIXTURE BP | Solution | Not listed in the data |
Safety Considerations
- Contraindications (from knowledge-graph associations, not label text): The drug is associated with contraindication links to kidney disease and impaired renal function, anuria, adrenal insufficiency (including Addison disease), hypertension, coronary artery disease and myocardial infarction, peptic ulcer disease, pancreatitis, diarrhoeal disease, metabolic acidosis, hypercalcaemia, rhabdomyolysis, nephrocalcinosis and benign prostatic hyperplasia, among others. These need confirmation against the package insert.
- Drug Interactions: 100 interactions are recorded. Major interactions include:
- ACE inhibitors and ARBs (benazepril, olmesartan, valsartan)
- Potassium-sparing diuretics (amiloride)
- Anticholinergics and antihistamines (atropine, hyoscyamine, homatropine, methscopolamine, chlorpheniramine, acrivastine, phenyltoloxamine)
- Amitriptyline
Moderate interactions include NSAIDs (ibuprofen, ketorolac), aspirin, aliskiren, doxycycline, amphetamines and pseudoephedrine.
- Key concern: Hyperkalaemia, especially with renal impairment or potassium-raising drugs.
Please also refer to the package insert for full warnings, as label text was not available for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism (raising urinary pH and citrate) is well established, and there is a completed Phase 3 trial (compared against potassium phosphate), a completed Phase 4 study, a systematic review and several reviews. However, no Phase 3 RCT result is documented in the data, the Phase 2/3 trial status is unknown, and the other Phase 2 trials are very small or withdrawn. Evidence is therefore L2. The use is also largely on-label rather than a true repurposing.
To proceed, the following is needed:
- Package insert warnings, contraindications and approved indications for the three Singapore registrations
- Mechanism of action data
- Results of the key trials, in particular NCT00004284, NCT06819553 and NCT06966635
- Monitoring plan: urinary pH, serum potassium and renal function, with caution in patients on ACE inhibitors, ARBs or potassium-sparing diuretics
- Other predictions (for example SLC26A1-related nephrolithiasis and exocrine pancreatic insufficiency with enteric hyperoxaluria) are research questions only. The remaining top-ranked predictions with no data should stay on Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.